GILD - Gilead Sciences, Inc.
| Previous close | 77.05 |
| Open | 0.00 |
| Bid | 76.84 x 100 |
| Ask | 77.16 x 300 |
| Day's range | 76.36 - 77.70 |
| 52-week range | 64.27 - 89.54 |
| Volume | 5,569,614 |
| Avg. volume | 7,286,976 |
| Market cap | 100.601B |
| Beta | 1.39 |
| PE ratio (TTM) | 29.43 |
| EPS (TTM) | 2.63 |
| Earnings date | 25 Jul 2018 |
| Forward dividend & yield | 2.28 (3.03%) |
| Ex-dividend date | 2018-06-14 |
| 1y target est | 86.00 |
- Motley Fool•19 hours ago
3 Key Things to Watch in Gilead Sciences' Q2 Earnings Report
These factors will be critical in the big biotech's Q2 update.
- Market Realist•3 days ago
Analysts’ Recommendations for Stryker and Its Peers in July
The SG&A expenses incurred by Stryker (SYK) are expected to increase 9.4% from $1.05 billion in the second quarter of 2017 to $1.15 billion in the second quarter. Total operating expenses incurred by Stryker are expected to reach $1.42 billion for the second quarter, compared with $1.49 billion for the second quarter of 2017. Analysts expect Stryker (SYK) to report net income of $549.25 million in the second quarter compared with $391.0 million in the second quarter of 2017, an increase of 40.47%.
- Zacks•3 days ago
Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?
Gilead (GILD) is likely to beat expectations in the second quarter propelled by the momentum in the HIV franchise.
Market Realist•3 days agoWhat Gilead Sciences’ Bottom Line Is Expected to Look Like in Q2
Gilead Sciences’ (GILD) selling, general, and administrative expenses are expected to increase 10.87%, from $827 million in Q2 2017 to $916.87 million in Q2 2018. Its research and development expenses are expected to increase 8.78%, from $812 million in Q2 2017 to $883.27 million in Q2 2018. Its expenses on stock-based compensation are expected to rise from $61 million in Q2 2017 to $194.33 million in Q2 2018.
Market Realist•3 days agoPossibilities for Gilead Sciences in Q2 2018 Earnings Release
Gilead Sciences (GILD) is expected to report its second-quarter earnings on July 25. Analysts expect Gilead Sciences’ revenues to decline 27.18%, from $7.14 billion in Q2 2017 to $5.2 billion in Q2 2018. In Q2 2017, its revenues shrunk 8.17%.
- Motley Fool•3 days ago
3 Top Healthcare Stocks to Buy in July
New products, bigger markets, and market-moving news could cause shares in these three companies to rally.
- MarketWatch•4 days ago
Gilead's Kite will partner with privately-held Gadeta to develop new cancer therapies
Gilead Sciences Inc. (GILD) said early Thursday that its Kite unit will partner with privately-held Gadeta B.V. to develop new cancer therapies called gamma delta T cell receptor therapies. Gadeta's proprietary technology in this area, which is a type of cell therapy, may be used to treat blood cancers and solid tumors. Kite will fund the research and development costs and buy equity in Gadeta, with the "exclusive option" to acquire Gadeta.
- Business Wire•4 days ago
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors
Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers. Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones.
- Business Wire•4 days ago
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors
Kite, a Gilead Company (GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers. Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones.
CNBC•5 days agoCramer's charts suggest big-name biotech stocks Gilead and Celgene have more room to run
Jim Cramer and technician Bob Lang inspect the charts to see if big-cap biotechnology stocks like Gilead and Celgene could have more room to run.
- Motley Fool•7 days ago
4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?
A game of musical chairs is coming to the HIV market.
- Motley Fool•8 days ago
3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018
Forget what's happened so far in 2018. These big pharma stocks look like great picks for the rest of the year.
- Motley Fool•9 days ago
3 Biotech Stocks With Big News Coming in NASH
The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.
- Business Wire•10 days ago
Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018
Gilead Sciences, Inc. (GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes. At 5:00 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2018 and provide a general business update. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 8988927 to access the call.
- Motley Fool•11 days ago
If You're Thinking About Buying Gilead Sciences Stock, Now's the Time to Do It
There's no time like the present to buy this big biotech stock.
- Zacks•13 days ago
The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna
The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna
- CNBC•13 days ago
Cramer's lightning round: Calling bottom in Southwest Airlines despite oil trends
Jim Cramer flies through his take on callers' favorite stocks, including an airline play feeling the heat.
- Business Wire•14 days ago
Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy
Kite, a Gilead Company (NASDAQ: GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy. In this position, Mr. Amoroso will have responsibility for Kite’s commercial organization including sales, marketing, market access, and healthcare provider and patient services.
- Business Wire•14 days ago
Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy
Kite, a Gilead Company (GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy. In this position, Mr. Amoroso will have responsibility for Kite’s commercial organization including sales, marketing, market access, and healthcare provider and patient services.
- Zacks•14 days ago
Top Research Reports for Mastercard, Gilead & Goldman Sachs
Top Research Reports for Mastercard, Gilead & Goldman Sachs
- Zacks•17 days ago
Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
- Zacks•17 days ago
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
- Barrons.com•18 days ago
Gilead: A Top Biotech Pick for a Turnaround
Shares of Gilead Sciences (GILD) have edged up slightly this year, trailing the broader market, but first data from the biotech's rheumatoid arthritis drug filgotinib, potentially in the next couple weeks, should keep investors bullish on the shares, says Jefferies' Michael Yee. Yee writes that comparable efficacy and clean safety will be key factors that could differentiate the drug from the competition and provide a positive read-through for its other, separate Ulcerative Colitis study. Together, data for filgotinib, along with the drug selonsertib for nonalcoholic steatohepatitis, could help Gilead grow earnings per share and expand its price-to-earnings ratio toward 15 times, he writes.
- Zacks•20 days ago
Is Gilead Sciences a Great Stock for Value Investors?
Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
- Zacks•21 days ago
Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion
Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.
